Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 23, Issue 2, 1999, Pages 145-150

  Michallet, M ^a   Perrin, M C ^a   Belhabri, A ^a   Molina, L ^b   Nicolini, F ^b   Tigaud, J D ^a   Sotto, J J ^b   Guyotat, D ^c   Fiere D ^a   Archimbaud, E ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

^c HÔPITAL NORD   (France)

Author keywords

BMT; Cyclosporine; Dose; GVHD therapy; Methylprednisolone; Relapse; Survival

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; RISK; SURVIVAL;

EID: 0032962646     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701529     Document Type: Article

References (38)

1. Ringden O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094-1101.
2. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 51: 443-447.
3. Glucksberg H, Storb R, Feter A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
4. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
5. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
6. Ferrara JLM, Krenger W, Cooke KR. Recent advances and future directions. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds). Graft-versus-Host Disease. Marcel Dekker: New York, 1996, pp 775-790.
7. Maraninchi D, Blaise D, Rio B et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukemias. Lancet 1987; 2: 175-178.
8. Pietryga D. Prevention and treatment of acute graft-versus-host disease. Am J Pediatr Hematol Oncol 1993; 15: 28-48.
9. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
10. Martin PJ, Schoch G, Fisher L et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464-1472.
11. Sullivan KM. Graft-versus-host disease. In: Blume KG, Petz LD (eds). Clinical Bone Marrow Transplantation. Churchill Livingstone: New York, 1983, pp 91-129.
12. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplant for leukemia. New Engl J Med 1986; 314: 729-735.
13. Gale RP, Bortin MM, Van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
14. Roy J, McGlave PB, Filipovich AH et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10: 77-82.
15. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. Bone Marrow Transplant 1994; 14: 601-607.
16. Hings IM, Severson R, Filipovich AH et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplant. Transplantation 1994; 58: 437-442.
17. Bacigalupo A, Van Lint MT, Frassoni F et al. High dose bolus methylprednisolone for treatment of acute graft-versus-host disease. Blut 1983; 46: 125-132.
18. Kanojia MD, Anagnostou AA, Zander AR et al. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984; 37: 246-249.
19. Oblon DJ, Felker D, Coyle K, Myers L. High-dose methylprednisolone therapy for acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation. Bone Marrow Transplant 1992; 10: 355-357.
20. Volgelsang GB, Hess AD, Santos GW. Acute graft-versus-host disease: clinical characteristics in the cyclosporine era. Medicine 1988; 67: 163-174.
21. Hings IM, Filipovich AH, Miller WJ et al. Prednisone therapy for acute graft-versus-host disease: short versus long-term treatment. Transplantation 1993; 56: 577-580.
22. Weiner RS, Horowitz MM, Gale RP et al. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. Br J Haematol 1989; 71: 535-543.
23. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New Engl J Med 1979; 300: 1068-1073.
24. Weiden PL, Sullivan KM, Flournoy N and the Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. New Engl J Med 1981; 304: 1529-1532.
25. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
26. Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: grade and outcome in patient with CML. Blood 1995; 86: 813-818.
27. Bacigalupo A, Van Lint MT, Occhini D et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
28. Hervé P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor a antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
29. Herbelin C, Stephan JL, Donadieu J et al. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Bone Marrow Transplant 1994; 13: 563-569.
30. Cahn JY, Bordigoni P, Tiberghien P et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multi center phase III study. Transplantation 1995; 60: 939-942.
31. Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342-1348.
32. Martin PJ, Nelson BJ, Appelbaum R et al. Evaluation of a CDS-specific immunotoxin for treatment of acute graft versus-host disease after allogeneic marrow transplantation. Blood 1996; 88: 824-830.
33. Racadot E, Milpied N, Bordigoni P et al. Sequential use of 3 monoclonal antibodies (MABS) in corticoresistant acute GVH. A multicentric pilot study in 15 patients. Blood 1994; 84: 207a.
34. Bonini C, Verzeletti S, Servida P et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity after allo BMT. Blood 1994; 84: 110a.
35. Couriel D, Cottler-Fox M, Burt RK et al. T-cell depleted marrow transplants with delayed lymphocyte add-back to prevent relapse in patients with leukemia and MDS. Blood 1994; 84: 334a.
36. + cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation 1994; 57: 82-87.
37. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
38. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.